Regeneron Pharmaceuticals (REGN) Payables: 2009-2025
Historic Payables for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $903.8 million.
- Regeneron Pharmaceuticals' Payables rose 81.74% to $903.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 33.63%. This contributed to the annual value of $789.5 million for FY2024, which is 30.15% up from last year.
- Regeneron Pharmaceuticals' Payables amounted to $903.8 million in Q3 2025, which was up 24.85% from $723.9 million recorded in Q2 2025.
- In the past 5 years, Regeneron Pharmaceuticals' Payables registered a high of $903.8 million during Q3 2025, and its lowest value of $427.0 million during Q3 2021.
- Its 3-year average for Payables is $649.4 million, with a median of $606.6 million in 2023.
- Per our database at Business Quant, Regeneron Pharmaceuticals' Payables tumbled by 74.68% in 2021 and then skyrocketed by 81.74% in 2025.
- Regeneron Pharmaceuticals' Payables (Quarterly) stood at $564.0 million in 2021, then grew by 4.47% to $589.2 million in 2022, then climbed by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024, then soared by 81.74% to $903.8 million in 2025.
- Its Payables was $903.8 million in Q3 2025, compared to $723.9 million in Q2 2025 and $705.5 million in Q1 2025.